Evotec AG has announced a research collaboration with privately-held Apeiron Biologics AG of Vienna, Austria to develop immunomodulatory lead compounds for cancer. Financial terms were not disclosed. The collaboration follows the successful outcome of a high throughput screen.
The US Food and Drug Administration has approved a botanical drug to relieve the symptoms of diarrhoea in HIV/AIDS patients taking antiretroviral therapy. The drug, Fulyzaq (crofelemer), is only the second botanical drug product to be approved by the agency.
The US Food and Drug Administration has authorised the first drug to treat multi-drug resistant tuberculosis involving the lungs in an accelerated approval based on a surrogate endpoint. The drug, Sirturo (bedaquiline), was discovered and developed by Johnson & Johnson Inc.
GlaxoSmithKline Plc of the UK said that top-line results from a Phase 3 trial of an experimental drug for Fabry disease failed to meet its primary endpoint of clearing a lipid substra
The European Medicines Agency has announced the start of a safety and efficacy review of Tredaptive (laropiprant and nicotinic acid), a licensed drug that recently completed a trial in combination with statin therapy for patients at risk of cardiovascular events.
Biotest AG of Germany has received approval from the US Food and Drug Administration to market its immunoglobulin product, Bivigam, in the US. The approval had been held up pending the completion of additional tests.
A new UK company has been launched with £11.5 million in venture capital funding to exploit a portfolio of preclinical and clinical neurokinin receptor antagonists divested from GlaxoSmithKline Plc. Novo A/S and Advent Venture Partners are investors.
The Swiss vaccine developer, GlycoVaxyn AG, is set to receive an upfront payment and equity investment from GlaxoSmithKline Biologicals as part of a collaboration to develop new anti-bacterial vaccines against an undisclosed set of pathogen targets.
Researchers at the Katholieke Universiteit in Leuven, Belgium have joined forces with two French pharmaceutical companies to discover new compounds targeting the LRRK2 gene in Parkinson’s disease.
Venture-capital backed Poxel SA of France has raised €13 million in a Series B round to support the clinical development of its lead product for Type 2 diabetes, Imeglimin. The financing was led by Edmond de Rothschild Investment Partners.